language Language

当サイトでは、機械的な自動翻訳サービスを使用しています。

Notification
This site may not be accurate due to machine translation, and all files (PDF, Excel, Word, PowerPoint) are not translated.

language Language

This site uses a machine translation service.

Notification
This site may not be accurate due to machine translation, and all files (PDF, Excel, Word, PowerPoint) are not translated.

Pharmaceuticals and Medical Devices Agency
menu
close
List of frequently viewed pages
Safety information, recall information, etc.
Search package inserts, etc.
Download various forms
About PMDA
About PMDA
Download various forms
Safety information, recall information, etc.
return
return
return
close
close

package inserts, Drug Guide for Patients,
Approval information and other information is
Click the Search by Product button.

review for (marketing) approval related work

quasi-drugs raw material standards

Add to Favorites
Print text only

Quasi quasi-drugs Standards 2021

  • Issued on March 21, 2025 (Reiwa 7)

　Partial revision of the "2021 quasi-drugs Standards" (Director-General's Notice) [2.18MB]PDF file (opens in a new window)

　Handling of applications for marketing approval of quasi-drugs following the partial revision of the "2021 quasi-drugs Raw Materials Standards" (Director's Notice) [99.22KB]PDF file (opens in a new window)

　Regarding the submission of errata for the 2021 quasi-drugs Standards (Part 2) (Administrative Notice) [195.01KB]PDF file (opens in a new window)

  • Issued on March 27, 2023 (Reiwa 5)

Partial Revision of the "2021 Standards for quasi-drugs Ingredients" (Director-General's Notice) [754.68KB]PDF file (opens in a new window)
Handling of applications for marketing approval of quasi-drugs following the partial revision of the "2021 quasi-drugs Raw Materials Standards" (Director's Notice) [111.44KB]PDF file (opens in a new window)

  • Issued on October 18, 2021 (Reiwa 3)

　Notification regarding the submission of errata for the 2021 Quasi quasi-drugs Standards (Administrative Notice) [127.87KB]PDF file (opens in a new window)

  • Issued on March 25, 2021 (Reiwa 3)

"Standards for quasi-drugs 2021" (Director-General's Notice) [283.45KB]PDF file (opens in a new window)

　"Quasi quasi-drugs Standards 2021" [13.01MB]PDF file (opens in a new window)

Handling of applications for marketing approval quasi-drugs following the revision of the "Standards for quasi-drugs Raw Materials" (Director's Notice) [80.62KB]PDF file (opens in a new window)